Faes Farma S.A./€FAE
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Faes Farma S.A.
Faes Farma S.A. is a pharmaceutical company engaged in the research, production, and marketing of pharmaceutical products. Headquartered in Leioa, Spain, the company operates primarily in the pharmaceuticals and animal health sectors. Key products include prescription medications for human health, over-the-counter medicines, and nutritional supplements, as well as products for veterinary use. Founded in 1933, Faes Farma has expanded its operations to various international markets, particularly in Europe and Latin America. Its competitive strength lies in its robust R&D capabilities and a well-established distribution network.
Ticker
€FAE
Sector
Primary listing
BME
Employees
1,894
Headquarters
Website
Faes Farma S.A. Metrics
BasicAdvanced
€1.3B
12.79
€0.34
0.35
€0.14
3.36%
Price and volume
Market cap
€1.3B
Beta
0.35
52-week high
€4.73
52-week low
€3.27
Average daily volume
63K
Dividend rate
€0.14
Financial strength
Current ratio
2.294
Quick ratio
1.454
Long term debt to equity
0.676
Total debt to equity
11.475
Dividend payout ratio (TTM)
46.39%
Interest coverage (TTM)
234.80%
Profitability
EBITDA (TTM)
117.148
Gross margin (TTM)
64.71%
Net profit margin (TTM)
19.37%
Operating margin (TTM)
18.70%
Effective tax rate (TTM)
-4.71%
Revenue per employee (TTM)
€290,000
Management effectiveness
Return on assets (TTM)
6.92%
Return on equity (TTM)
14.83%
Valuation
Price to earnings (TTM)
12.789
Price to revenue (TTM)
2.467
Price to book
1.84
Price to tangible book (TTM)
2.63
Price to free cash flow (TTM)
18.491
Free cash flow yield (TTM)
5.41%
Free cash flow per share (TTM)
0.233
Dividend yield (TTM)
3.36%
Growth
Revenue change (TTM)
10.13%
Earnings per share change (TTM)
7.99%
3-year revenue growth (CAGR)
5.31%
10-year revenue growth (CAGR)
10.36%
3-year earnings per share growth (CAGR)
5.93%
10-year earnings per share growth (CAGR)
11.58%
Bulls say / Bears say
First-half 2025 revenues surged 12.3% year-over-year to €307.4 million and adjusted EBITDA grew 2.5% to €80.5 million, reflecting strong operational momentum across all segments. (Investing.com)
The acquisition of Portugal’s Laboratorios Edol for €75 million strengthens Faes Farma’s ophthalmology portfolio, doubling its sales footprint in Portugal and supporting the 2030 ambition to reach €1 billion in revenues. (Cinco Días)
The 2025–2030 strategic plan commits to raising R&D investment from 6% to 10% of pharmaceutical sales by 2030, underpinning sustainable pipeline development and innovation capacity. (Reuters)
EBITDA for H1 2025 fell 6.6% to €73.3 million and net profit declined 10.5% to €52.2 million due to one-off costs related to the new Derio plant and M&A expenses, indicating margin pressure from expansion initiatives. (Investing.com)
Following the SIFI acquisition, Faes Farma’s net debt/EBITDA ratio is expected to reach approximately 2×, increasing financial leverage and raising risk should market conditions worsen. (Cinco Días)
The deal structure includes contingent earn-outs of up to €50.5 million in Europe plus a potential €30 million for the US launch of Akantior, introducing execution and cash-flow uncertainty if sales targets are not met. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Faes Farma S.A. stock?
Faes Farma S.A. (FAE) has a market cap of €1.3B as of September 14, 2025.
What is the P/E ratio for Faes Farma S.A. stock?
The price to earnings (P/E) ratio for Faes Farma S.A. (FAE) stock is 12.79 as of September 14, 2025.
Does Faes Farma S.A. stock pay dividends?
Yes, the Faes Farma S.A. (FAE) stock pays dividends to shareholders. As of September 14, 2025, the dividend rate is €0.14499 and the yield is 3.36%. Faes Farma S.A. has a payout ratio of 46.39% on a trailing twelve-month basis.
When is the next Faes Farma S.A. dividend payment date?
The next Faes Farma S.A. (FAE) dividend payment date is unconfirmed.
What is the beta indicator for Faes Farma S.A.?
Faes Farma S.A. (FAE) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.